Notice of Allowability	Application No.	Applicant(s)
	10/002,959	
	Examiner	CHEVALIER ET AL. Art Unit
	Gina C. Yu	1617
The MAILING DATE of this communication ap All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOL-8 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.3 1. This communication is responsive to Amendment filed of 2. The allowed claim(s) is/are 18-27, which are renumbered 3. The drawings filed on are accepted by the Examinate 4. Acknowledgment is made of a claim for foreign priority a) All b) Some* c) None of the: 1. Certified copies of the priority documents hat 2. Certified copies of the priority documents hat 3. Copies of the certified copies of the priority of International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE noted below. Failure to timely comply will result in ABANDON THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be subinisted in the proper No. Mail Date 1) hereto or 2) to Paper No. Mail Date 1) hereto or 2) to Paper No. Mail Date 1) hereto or 2) to Paper No. Mail Date 1 dentifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in the paper No. Mail Date Replacement sheet(s) should be labeled as such in the paper No. Mail Date Replacement sheet(s) should be labeled as such in the deponent sheet. Replacement sheet(s) should be labeled as such in the paper No. Mail Date Replacement sheet(s) should be labeled as such in the deponent sheet. Replacement sheet(s) should be labeled as such in the deponent sheet. Replacement sheet(s) should be labeled as such in the deponent sheet. Replacement sheet(s) should be labeled as such in the deponent sheet. Replacement sheet(s) should be labeled as such in the deponent sheet. Replacement sheet(s) should be labeled as such in the deponent sheet sheet.	IS (OR REMAINS) CLOSED (S5) or other appropriate commercent of the submitted of the submitt	in this application. If not included nunication will be mailed in due course. THIS is subject to withdrawal from issue at the initiative of the course of the initiative of the course of the mailed in due course. THIS is subject to withdrawal from issue at the initiative of the course of the initiative of the course of the initiative of the course of
attached Examiner's comment regarding REQUIREMENT Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date Paper No./Mail Date 5. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. Notice of Interview St. Paper No./ 7. Examiner's	formal Patent Application (PTO-152) Jummary (PTO-413), Mail Date Amendment/Comment Statement of Reasons for Allowance

Application/Control Number: 10/002,959

Art Unit: 1617

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

In the specification, before "BACKGROUND OF INVENTION", insert "CROSS REFERENCE TO RELATED APPLICATION ¶ The present application is a Continuation of application serial no. 09/522,106, now U.S. Pat. No. 6,337,077."

Terminal Disclaimer

The terminal disclaimer filed on May 10, 2004 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US. Pat. No. 6337077 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Allowable Subject Matter

Claims 18-27 are allowed. The following is an examiner's statement of reasons for allowance: The obvious double patenting rejection made over U.S. Pat. No. 6337077 as indicated in the previous Office action dated February 13, 2004 is withdrawn in view of the terminal disclaimer filed on May 10, 2004. The claim rejection made under 35 U.S.C. § 112, first par. as indicated in the same Office action is withdrawn in view of the cancellation of claims 28-37, which were the only claims subject to the rejection under § 112.

Application/Control Number: 10/002,959

Art Unit: 1617

Although U.S. Pat. No. 5840701 teaches that L-2-oxothiazolidine-4-carboxylic acid (procysteine) is a GSH (glutathione) precursor and can enhance body's natural antioxidant capacity, the reference also indicates that it is unable to deal with the higher levels of free radicals encountered in injury and disease, and is rapidly consumed by the body. See col. 2, lines 56 – 61. Furthermore, there is no teaching of topical use of the compound. It is viewed that, although procysteine is well-known pharmaceutical art, the claimed method of topically using the compound in protecting skin from light-induced aging and/or environment-related stress would not have been obvious to one of ordinary skill in the art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gina C. Yu whose telephone number is 571-272-0635.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/002,959

Art Unit: 1617

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gina Yu Patent Examiner

> SREENI PADMANABHAN SUPERVISORY PAYENY EXAMINER